Negative news about Genting's associate TauRX Pharmaceuticals Ltd’s unsuccessful experimental results for its Alzheimer’s drug, LMTX, also weighed on the share price. Also dragging down the market was the slump in crude oil prices.
Already a subscriber? Log in
Get 20% OFF The Star Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
